首页|芪黄健脾滋肾方在脾肾两虚型系统性红斑狼疮患者达标治疗中的临床疗效观察

芪黄健脾滋肾方在脾肾两虚型系统性红斑狼疮患者达标治疗中的临床疗效观察

扫码查看
目的:观察芪黄健脾滋肾方治疗脾肾两虚型系统性红斑狼疮及其在达标治疗中的的临床疗效。方法:将60例患者(SLE)采用随机数表法分为治疗组与对照组,两组各30例患者。对照组给予基础治疗,治疗组在基础治疗上另服芪黄健脾滋肾方,疗程12 w。评估临床疗效、中医证候总积分、疾病活动度(SLEDAI)、医生整体评估(PGA)、英岛狼疮评定组指数(BILAG);检测白细胞计数(WBC)、红细胞计数(RBC)、血红蛋白(HGB)、血小板计数(PLT)、红细胞压积(HCT)、平均红细胞体积(MCV)、网织红细胞计数(RET)、免疫系统指标(IgG、IgA、IgM、C3、C4)、胱抑素(cys)、红细胞沉降率(ESR)、C反应蛋白(CRP)、血管内皮生长因子(VEGF)及安全性指标。结果:与治疗前比较,两组治疗后SLEDAI、PGA、BILAG评分、中医证候评分(头晕耳鸣、面部红斑、脱发、食少纳呆、腰膝酸痛)、IgG、IgA、Cysc、ESR、VEGF、CRP 含量降低(P<0。05);WBC、RBC、HGB、PLT、HCT、MCV、RET、IgM、C3、C4 水平升高(P<0。05);治疗后,治疗组SLEDAI、PGA、BILAG评分、中医证候评分(神疲体倦、头晕耳鸣、面部红斑、脱发、失眠多梦、食少纳呆、腰膝酸痛、大便干结)、炎症指标(ESR、CRP、VEGF)、IgG、IgA、Cysc明显低于对照组(P<0。05),血液系统指标(WBC、PLT、RBC、HCT、MCV)、C3、C4高于对照组(P<0。05)。治疗组的临床治疗总有效率(93。33%)优于对照组的(60。0%)(P<0。05),安全性也更高。结论:芪黄健脾滋肾方与甲泼尼龙、硫酸羟氯喹同用对改善系统性红斑狼疮疾病活动度等临床疗效指标效果显著,有很大的临床应用价值。
Clinical Efficacy of Qihuang Jianpi Zishen Granules(芪黄健脾滋肾方)in Treating Patients with Systemic Lupus Erythematosus
Objective:To observe the clinical efficacy of Qihuang Jianpi Zishen Granules(黄健脾滋肾方)in the treatment of patients with sys-temic lupus erythematosus(SLE).Methods:Sixty patients with SLE were assigned into an observation group(n=30)and a control group(n=30)by the random number table method.The control group received basic treatment,and the observation group received basic treatment combined with Qihuang Jianpi Zishen Granules.The treatment in both groups lasted for 12 weeks.The clinical efficacy,TCM symptom scores,disease activity index(SLEDAI),physician's global assessment(PGA)score,and British Isles lupus assessment group(BILAG)in-dex,white blood cell count(WBC),red blood cell count(RBC),hemoglobin(HGB),platelet count(PLT),hematocrit(HCT),mean eryth-rocyte volume(MCV),reticulocyte count(RET),immunoglobulin G(IgG),Immunoglobulin A(IgA),immunoglobulin M(IgM),comple-ment 3(C3),complement 4(C4),cystatin C(CysC),erythrocyte sedimentation rate(ESR),C-reactive protein(CRP),vascular endothelial growth factor(VEGF),and safety index were determined.Results:Compared with those before treatment,the SLEDAI score,PGA score,BI-LAG index,TCM symptom scores(dizziness,tinnitus,facial erythema,hair loss,reduced appetite,and waist and knee soreness),and IgG,IgA,Cysc,ESR,VEGF,and CRP levels declined(P<0.05),while the levels of WBC,RBC,HGB,PLT,HCT,MCV,RET,IgM,C3,and C4 elevated(P<0.05)in the two groups after treatment.After treatment,the observation group had lower SLEDAI score,PGA score,BILAG in-dex,TCM syndrome scores(fatigue,dizziness and tinnitus,facial erythema,hair loss,insomnia and dreamful sleep,reduced appetite,waist and knee soreness,and dry stool),inflammation indicator levels(ESR,CRP,and VEGF),IgG,IgA,and CysC(P<0.05)and higher levels of WBC,PLT,RBC,HCT,MCV,C3,and C4 than the control group(P<0.05).The observation group had higher total response rate(93.33%vs.60.0%,P<0.05)and higher safety than the control group.Conclusion:Qihuang Jianpi Zishen Granules combined with methylpred-nisolone and hydroxychloroquine sulfate have definite efficacy in recovering the clinical indicators including SLEDAI,demonstrating a great application value in clinical practice.

Qihuang Jianpi Zishen Granules(芪黄健脾滋肾方)Systemic lupus erythematosusTreat-to-targetClinical efficacy

李云飞、庞利君、束龙武、付皖兰、尚双双、李明、黄传兵

展开 >

安徽中医药大学研究生院,合肥 230031

安徽中医药大学第一附属医院风湿免疫科,合肥 230031

芪黄健脾滋肾方 系统性红斑狼疮 达标治疗 临床疗效

2024

中药药理与临床
中国药理学会 四川省中医药科学院

中药药理与临床

北大核心
影响因子:0.996
ISSN:1001-859X
年,卷(期):2024.40(11)